Sean Harp­er and Beth Sei­den­berg add $500M to their new VC, bet­ting on the LA biotech ecosys­tem

When Ar­se­nal Bio launched last year, the head­line name was Nap­ster bil­lion­aire Sean Park­er, who, af­ter fund­ing an im­munother­a­py in­sti­tute, de­cid­ed to back a bold bet on cell ther­a­py 2.0.

The first in­vestor named on the press re­lease for Ar­se­nal’s $85 mil­lion launch, though, wasn’t Park­er; it was West­lake Vil­lage Biopart­ners, an LA-based VC firm found­ed just the year pri­or by long­time Am­gen R&D chief Sean Harp­er and the long­time life sci­ences chief at the leg­endary Sil­i­con Val­ley firm Klein­er Perkins, Beth Sei­den­berg.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER